Stay Updated
For all press requests, please reach out to [email protected].
News and Reports
STAT: Trump proposal to lower drug prices targets insurer, PBM rebates
November 17 Erin Mershon The Trump administration is exploring policy changes that could eventually lower the prices Medicare beneficiaries pay at the pharmacy counter. Although it’s only a small, initial step in that direction, it’s one of the first signals of how the Trump administration is trying to deliver on the president’s promises to lower […]
News and Reports
STAT: Allergan invokes the victim defense to protect a brand-name drug from a generic challenge
November 3 David Mitchell Allergan, a multibillion-dollar drug corporation, is attempting to perpetrate a fraud on the American people that would make Bernie Madoff blush — even as it casts itself as a victim. Allergan makes several products, including Restasis, a very expensive brand-name drug that people with dry eye and related conditions take to […]
News and Reports
KelloggInsight: Prescription Drug Coupons Actually Increase Healthcare Spending by Billions
October 3 Based on the research of Leemore Dafny, Christopher Ody and Matt Schmitt Last year, the pharmaceutical company Mylan faced public outcry when it raised the price of the lifesaving allergy medication EpiPen to $609 a box. In response to the furor, Mylan pointed out it offers copay coupons that can reduce consumers’ out-of-pocket […]
News and Reports
KHN: Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don’t We?
September 25 Jay Hancock Of all the promises President Donald Trump made for the early part of his term, controlling stinging drug prices might have seemed the easiest to achieve. An angry public overwhelmingly wants change in an easily vilified industry. Big pharma’s recent publicity nightmare included thousand-percent price increases and a smirking CEO who […]
News and Reports
Patients For Affordable Drugs Calls on PhRMA to Disavow Allergan’s Latest Legal Maneuvers
Patients For Affordable Drugs sent the following letter on Wednesday, September 13, to PhRMA President and CEO Stephen J. Ubl. Dear Mr. Ubl, Your website states: “Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.” Your mission does not include […]
News and Reports
The Atlantic: The Cancer Patient Taking On High Drug Prices
September 6 Sarah Zhang David Mitchell, 66, has multiple myeloma, a blood cancer that is incurable but treatable. To stay alive, he takes $440,000 worth of drugs a year. Mitchell counts himself as lucky. He has Medicare and can afford to buy Medicare Supplement Plan B, so his insurance covers his drugs. But not everyone […]
News and Reports
FiercePharma: Novartis CEO opens door to cancer patient demanding 'fair' CAR-T pricing
August 21 Arlene Weintraub David Mitchell had just finished a five-hour infusion of drugs to keep his multiple myeloma under control when he decided to dash off a letter to Joe Jimenez, CEO of Novartis, requesting a meeting about how the company plans to price tisagenlecleucel (CTL019), its CAR-T leukemia treatment expected to win approval […]
News and Reports
USA Today: FDA Chief Says Drug Makers are Gaming the System to Slow Generic Competition; Vows Action
August 15 Jayne O’Donnell A day after President Trump lashed out at the black CEO of drug maker Merck on Twitter, his new Food and Drug Administration commissioner said brand name drug companies are “gaming the system” to block generic competition and vowed to do something about it. Physician and FDA chief Scott Gottlieb declined […]